首页 > 最新文献

Revista Espanola De Medicina Nuclear E Imagen Molecular最新文献

英文 中文
Tejido esplénico intrapancreático simulando tumor neuroendocrino 胰腺内脾组织模拟神经内分泌肿瘤
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-09-01 DOI: 10.1016/j.remn.2024.500031
S. Rama Alonso, P. García-Talavera San Miguel, A.C. Peñaherrera Cepeda, E. Campaña Díaz, J.A. Badell Martínez, F. Gómez-Caminero López
{"title":"Tejido esplénico intrapancreático simulando tumor neuroendocrino","authors":"S. Rama Alonso, P. García-Talavera San Miguel, A.C. Peñaherrera Cepeda, E. Campaña Díaz, J.A. Badell Martínez, F. Gómez-Caminero López","doi":"10.1016/j.remn.2024.500031","DOIUrl":"10.1016/j.remn.2024.500031","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 5","pages":"Article 500031"},"PeriodicalIF":1.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142168059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resección incompleta en un raro caso de paraganglioma vesical evidenciado mediante 123I-MIBG SPECT/TC con diurético 123I-MIBG SPECT/CT 显示一例罕见的膀胱副神经节瘤在服用利尿剂后切除不彻底
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-09-01 DOI: 10.1016/j.remn.2024.500018
A. Padilla Bermejo, J. Gatón Ramírez, F.J. Pena Pardo, M. de las Nieves Sicilia Pozo, M. del Prado Talavera Rubio, V. Poblete García
{"title":"Resección incompleta en un raro caso de paraganglioma vesical evidenciado mediante 123I-MIBG SPECT/TC con diurético","authors":"A. Padilla Bermejo, J. Gatón Ramírez, F.J. Pena Pardo, M. de las Nieves Sicilia Pozo, M. del Prado Talavera Rubio, V. Poblete García","doi":"10.1016/j.remn.2024.500018","DOIUrl":"10.1016/j.remn.2024.500018","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 5","pages":"Article 500018"},"PeriodicalIF":1.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142168060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Asociación entre la inflamación cardiovascular y los cambios del sistema inmune inducidos por la infección por VIH mediante PET/RM con [18F]FDG 利用[18F]FDG PET/MR分析心血管炎症与艾滋病毒诱发的免疫系统变化之间的关系
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-09-01 DOI: 10.1016/j.remn.2024.500042
J.R. Garcia , R. Olivero , I. Arrieta-Aldea , J.A. Romero , E. Riera , E. Cañas-Ruano , N. Garrido , J. Du , R. Guerri

Objective

To assess by [18F]FDG PET/MR the biomarkers of HIV-induced inflammation at baseline and 1 year post-antiretroviral therapy (ART).

Methods

Prospective study, 14 patients, newly diagnosed HIV-positive, asymptomatic.

[18F]FDG PET/MRI (PET/MR-3.0 T, Signa.GE) whole body and heart was performed, baseline and 1 year post-ART.

Qualitative vascular assessment (hepatic reference). Quantitative assessment (SUVmax) of the whole body. T1 and T2 value estimation in 16 myocardial segments.

Results

Baseline CMR showed in 3 (21.4%) a decreased LVEF, normalising post-TAR. Fibrosis was ruled out (T1), with no signs of myocardial oedema (T2) at baseline or post-TAR.

Four (28.6%) showed baseline vascular [18F]FDG uptake, two in ascending thoracic aorta and two in ascending and descending thoracic aorta, normalising post-TAR.

All (100%) showed basal lymph-nodes activity; supra (n:14) and infradiaphragmatic (n:13), laterocervical (n:14) and inguinal (n:13), with variable number of territories (9 patients >6; 64.3%). Post-ART, 7 patients (50%) showed resolution and the other 7 reduction in extension (0 patients >5): 7 supra (100%) and 2 infradiaphragmatic (28.6%), 5 in the axilla and 2 in the groin.

All (100%) had persistent basal adenoid uptake post-ART, 9 (64.3%) splenic all resolved post-ART and 7 (50.5%) gastric, persistent 3 post-ART.

Conclusions

Cardiovascular biomarkers by [18F]FDG PET/MR have shown baseline 28.6% of patients with large vessel activity and 21.4% with low LVEF, normalising post-ART.

Inflammatory/immune biomarkers showed baseline activity in 100% of lymph-nodes, 100% adenoids, 64.3% splenic and 50.5% gastric. Post-TAR the reduction was 50% lymph-nodes, 0% adenoid, 100% splenic and 57.1% gastric.

通过[18F]FDG PET/MR评估抗逆转录病毒疗法(ART)基线和治疗后 1 年的 HIV 引起的炎症的生物标志物。方法:对 14 名新诊断为 HIV 阳性、无症状的患者进行回顾性研究。全身定量评估(SUVmax)。结果基线 CMR 显示 3 例(21.4%)患者 LVEF 下降,TAR 后恢复正常。4人(28.6%)显示基线血管[18F]FDG摄取,其中2人在升胸主动脉,2人在升胸主动脉和降胸主动脉,TAR后恢复正常。所有淋巴结(100%)均显示基底淋巴结活动;膈上(14 个)和膈下(13 个)、颈后(14 个)和腹股沟(13 个),淋巴结区域数量不一(9 例患者 >6;64.3%)。ART 后,7 名患者(50%)的病症得到缓解,另外 7 名患者的病症扩展范围缩小(0 名患者 >5):所有患者(100%)在ART 后都有持续的基底腺样体摄取,9 例(64.3%)脾脏患者在ART 后全部消退,7 例(50.5%)胃部患者在ART 后持续 3 个月。通过[18F]FDG PET/MR检测心血管生物标志物显示,28.6%的患者基线有大血管活动,21.4%的患者有低LVEF,这些情况在ART后趋于正常。TAR后,淋巴结的活性降低了50%,腺样体降低了0%,脾脏降低了100%,胃降低了57.1%。
{"title":"Asociación entre la inflamación cardiovascular y los cambios del sistema inmune inducidos por la infección por VIH mediante PET/RM con [18F]FDG","authors":"J.R. Garcia ,&nbsp;R. Olivero ,&nbsp;I. Arrieta-Aldea ,&nbsp;J.A. Romero ,&nbsp;E. Riera ,&nbsp;E. Cañas-Ruano ,&nbsp;N. Garrido ,&nbsp;J. Du ,&nbsp;R. Guerri","doi":"10.1016/j.remn.2024.500042","DOIUrl":"10.1016/j.remn.2024.500042","url":null,"abstract":"<div><h3>Objective</h3><p>To assess by [<sup>18</sup>F]FDG PET/MR the biomarkers of HIV-induced inflammation at baseline and 1 year post-antiretroviral therapy (ART).</p></div><div><h3>Methods</h3><p>Prospective study, 14 patients, newly diagnosed HIV-positive, asymptomatic.</p><p>[<sup>18</sup>F]FDG PET/MRI (PET/MR-3.0<!--> <!-->T, Signa.GE) whole body and heart was performed, baseline and 1 year post-ART.</p><p>Qualitative vascular assessment (hepatic reference). Quantitative assessment (SUVmax) of the whole body. T1 and T2 value estimation in 16 myocardial segments.</p></div><div><h3>Results</h3><p>Baseline CMR showed in 3 (21.4%) a decreased LVEF, normalising post-TAR. Fibrosis was ruled out (T1), with no signs of myocardial oedema (T2) at baseline or post-TAR.</p><p>Four (28.6%) showed baseline vascular [<sup>18</sup>F]FDG uptake, two in ascending thoracic aorta and two in ascending and descending thoracic aorta, normalising post-TAR.</p><p>All (100%) showed basal lymph-nodes activity; supra (n:14) and infradiaphragmatic (n:13), laterocervical (n:14) and inguinal (n:13), with variable number of territories (9 patients<!--> <!-->&gt;6; 64.3%). Post-ART, 7 patients (50%) showed resolution and the other 7 reduction in extension (0 patients<!--> <!-->&gt;5): 7 supra (100%) and 2 infradiaphragmatic (28.6%), 5 in the axilla and 2 in the groin.</p><p>All (100%) had persistent basal adenoid uptake post-ART, 9 (64.3%) splenic all resolved post-ART and 7 (50.5%) gastric, persistent 3 post-ART.</p></div><div><h3>Conclusions</h3><p>Cardiovascular biomarkers by [<sup>18</sup>F]FDG PET/MR have shown baseline 28.6% of patients with large vessel activity and 21.4% with low LVEF, normalising post-ART.</p><p>Inflammatory/immune biomarkers showed baseline activity in 100% of lymph-nodes, 100% adenoids, 64.3% splenic and 50.5% gastric. Post-TAR the reduction was 50% lymph-nodes, 0% adenoid, 100% splenic and 57.1% gastric.</p></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 5","pages":"Article 500042"},"PeriodicalIF":1.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142168702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pseudoaneurisma poplíteo de etiología micótica 真菌引起的腘窝假动脉瘤
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-09-01 DOI: 10.1016/j.remn.2024.500025
M.P. Cózar Santiago , J.R. García Garzón , A. Esteban Hurtado , J. Ferrer Rebolleda
{"title":"Pseudoaneurisma poplíteo de etiología micótica","authors":"M.P. Cózar Santiago ,&nbsp;J.R. García Garzón ,&nbsp;A. Esteban Hurtado ,&nbsp;J. Ferrer Rebolleda","doi":"10.1016/j.remn.2024.500025","DOIUrl":"10.1016/j.remn.2024.500025","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 5","pages":"Article 500025"},"PeriodicalIF":1.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142168058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radioteragnosis en paragangliomas y feocromocitomas 副神经节瘤和嗜铬细胞瘤的放射诊断
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-07-01 DOI: 10.1016/j.remn.2024.500017

This continuing education aims to present in a clear and easy-to-understand manner the biology of paragangliomas and pheochromocytomas (PPGLs), the functional imaging studies available for their diagnosis and therapeutic planning, the requirements necessary to administer radioligand therapy (RLT) and the characteristics of these treatments (inclusion criteria, administration protocols, adverse effects and future perspectives).

In this pathology we have two RLT options: [131I]MIBG and [177Lu]Lu-DOTA-TATE. The indication for treatment is determined by the expression of its therapeutic target in functional imaging studies, allowing precision and personalized medicine.

Although most of the results we have for both treatments have as origin small retrospective series, RLT is presented as a safe and well-tolerated therapeutic option in PPGLs with slow-moderate progression or with uncontrollable symptoms, obtaining high disease control rates.

本次继续教育旨在以清晰易懂的方式介绍副神经节瘤和嗜铬细胞瘤(PPGLs)的生物学特性、可用于诊断和治疗计划的功能成像研究、实施放射性配体疗法(RLT)的必要条件以及这些疗法的特点(纳入标准、实施方案、不良反应和未来展望):在这种病理情况下,我们有两种放射性同位素治疗选择:[131I]MIBG 和 [177Lu]Lu-DOTA-TATE。治疗的适应症由功能成像研究中治疗靶点的表达决定,从而实现精准和个性化医疗。虽然我们对这两种治疗方法的大多数结果都是小规模的回顾性系列研究,但 RLT 被认为是一种安全、耐受性良好的治疗方案,适用于病情发展缓慢或症状无法控制的 PPGL,可获得较高的疾病控制率。
{"title":"Radioteragnosis en paragangliomas y feocromocitomas","authors":"","doi":"10.1016/j.remn.2024.500017","DOIUrl":"10.1016/j.remn.2024.500017","url":null,"abstract":"<div><p>This continuing education aims to present in a clear and easy-to-understand manner the biology of paragangliomas and pheochromocytomas (PPGLs), the functional imaging studies available for their diagnosis and therapeutic planning, the requirements necessary to administer radioligand therapy (RLT) and the characteristics of these treatments (inclusion criteria, administration protocols, adverse effects and future perspectives).</p><p>In this pathology we have two RLT options: [<sup>131</sup>I]MIBG and [<sup>177</sup>Lu]Lu-DOTA-TATE. The indication for treatment is determined by the expression of its therapeutic target in functional imaging studies, allowing precision and personalized medicine.</p><p>Although most of the results we have for both treatments have as origin small retrospective series, RLT is presented as a safe and well-tolerated therapeutic option in PPGLs with slow-moderate progression or with uncontrollable symptoms, obtaining high disease control rates.</p></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 4","pages":"Article 500017"},"PeriodicalIF":1.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141405964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Análisis de confiabilidad y lectibilidad de ChatGPT-4 y Google Gard como fuente de información del paciente para los tratamientos con radionúclidos más comúnmente aplicados en pacientes con cáncer 将 ChatGPT-4 和 Google Gard 作为癌症患者最常用放射性核素治疗的患者信息来源的可靠性和可讲性分析。
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-07-01 DOI: 10.1016/j.remn.2024.500021
H. Şan , Ö. Bayrakçi , B. Çağdaş , M. Serdengeçti , E. Alagöz
<div><h3>Purpose</h3><p>Searching for online health information is a popular approach employed by patients to enhance their knowledge for their diseases. Recently developed AI chatbots are probably the easiest way in this regard. The purpose of the study is to analyze the reliability and readability of AI chatbot responses in terms of the most commonly applied radionuclide treatments in cancer patients.</p></div><div><h3>Methods</h3><p>Basic patient questions, thirty about RAI, PRRT and TARE treatments and twenty-nine about PSMA-TRT, were asked one by one to GPT-4 and Bard on January 2024. The reliability and readability of the responses were assessed by using DISCERN scale, Flesch Reading Ease(FRE) and Flesch-Kincaid Reading Grade Level(FKRGL).</p></div><div><h3>Results</h3><p>The mean (SD) FKRGL scores for the responses of GPT-4 and Google Bard about RAI, PSMA-TRT, PRRT and TARE treatments were 14.57 (1.19), 14.65 (1.38), 14.25 (1.10), 14.38 (1.2) and 11.49 (1.59), 12.42 (1.71), 11.35 (1.80), 13.01 (1.97), respectively. In terms of readability the FRKGL scores of the responses of GPT-4 and Google Bard about RAI, PSMA-TRT, PRRT and TARE treatments were above the general public reading grade level. The mean (SD) DISCERN scores assesses by nuclear medicine phsician for the responses of GPT-4 and Bard about RAI, PSMA-TRT, PRRT and TARE treatments were 47.86 (5.09), 48.48 (4.22), 46.76 (4.09), 48.33 (5.15) and 51.50 (5.64), 53.44 (5.42), 53 (6.36), 49.43 (5.32), respectively. Based on mean DISCERN scores, the reliability of the responses of GPT-4 and Google Bard about RAI, PSMA-TRT, PRRT, and TARE treatments ranged from fair to good. The inter-rater reliability correlation coefficient of DISCERN scores assessed by GPT-4, Bard and nuclear medicine physician for the responses of GPT-4 about RAI, PSMA-TRT, PRRT and TARE treatments were 0.512 (95% CI 0.296: 0.704), 0.695 (95% CI 0.518: 0.829), 0.687 (95% CI 0.511: 0.823) and 0.649 (95% CI 0.462: 0.798), respectively (<em>P</em><.01). The inter-rater reliability correlation coefficient of DISCERN scores assessed by GPT-4, Bard and nuclear medicine physician for the responses of Bard about RAI, PSMA-TRT, PRRT and TARE treatments were 0.753 (95% CI 0.602: 0.863), 0.812 (95% CI 0.686: 0.899), 0.804 (95% CI 0.677: 0.894) and 0.671 (95% CI 0.489: 0.812), respectively (<em>P</em><.01). The inter-rater reliability for the responses of Bard and GPT-4 about RAİ, PSMA-TRT, PRRT and TARE treatments were moderate to good. Further, consulting to the nuclear medicine physician was rarely emphasized both in GPT-4 and Google Bard and references were included in some responses of Google Bard, but there were no references in GPT-4.</p></div><div><h3>Conclusion</h3><p>Although the information provided by AI chatbots may be acceptable in medical terms, it can not be easy to read for the general public, which may prevent it from being understandable. Effective prompts using ‘prompt engineering’ may refine the responses
目的搜索在线健康信息是患者常用的一种方法,以增强他们对疾病的了解。最近开发的人工智能聊天机器人可能是这方面最简单的方法。本研究的目的是分析人工智能聊天机器人就癌症患者最常使用的放射性核素治疗方法所做回答的可靠性和可读性。方法在 2024 年 1 月向 GPT-4 和 Bard 逐一询问了患者的基本问题,其中 30 个是关于 RAI、PRRT 和 TARE 治疗的,29 个是关于 PSMA-TRT 的。采用 DISCERN 量表、Flesch Reading Ease(FRE)和 Flesch-Kincaid Reading Grade Level(FKRGL)对回答的可靠性和可读性进行了评估。结果 GPT-4 和 Google Bard 中关于 RAI、PSMA-TRT、PRRT 和 TARE 治疗的回答的 FKRGL 平均得分(标清)分别为 14.57(1.19)、14.65(1.38)、14.25(1.10)、14.38(1.2)和 11.49(1.59)、12.42(1.71)、11.35(1.80)、13.01(1.97)。就可读性而言,关于 RAI、PSMA-TRT、PRRT 和 TARE 治疗的 GPT-4 和 Google Bard 的 FRKGL 分数高于一般公众的阅读水平。核医学医生对 GPT-4 和谷歌巴德关于 RAI、PSMA-TRT、PRRT 和 TARE 治疗的回答进行评估后得出的 DISCERN 平均分(标度)分别为 47.86(5.09)、48.48(4.22)、46.76(4.09)、48.33(5.15)和 51.50(5.64)、53.44(5.42)、53(6.36)、49.43(5.32)。根据 DISCERN 平均得分,GPT-4 和 Google Bard 关于 RAI、PSMA-TRT、PRRT 和 TARE 治疗的回答的可靠性从一般到良好不等。由 GPT-4、谷歌巴德和核医学医生对 GPT-4 关于 RAI、PSMA-TRT、PRRT 和 TARE 治疗的回答所评估的 DISCERN 分数的评分者间可靠性相关系数为 0.512(95% CI 0.296:0.704)、0.695(95% CI 0.518:0.829)、0.687(95% CI 0.511:0.823)和 0.649(95% CI 0.462:0.798)(P<.01)。由 GPT-4、Bard 和核医学医生评估的 Bard 关于 RAI、PSMA-TRT、PRRT 和 TARE 治疗的 DISCERN 评分的评分者间可靠性相关系数分别为 0.753(95% CI 0.602:0.863)、0.812(95% CI 0.686:0.899)、0.804(95% CI 0.677:0.894)和 0.671(95% CI 0.489:0.812)(P<.01)。Bard和GPT-4对RAİ、PSMA-TRT、PRRT和TARE治疗的反应的评分者间可靠性为中等至良好。此外,GPT-4 和 Google Bard 很少强调向核医学医生咨询,Google Bard 的一些回答中包含了参考文献,但 GPT-4 中没有参考文献。使用 "提示工程 "进行有效提示可能会以更易于理解的方式完善回复。由于放射性核素治疗是核医学专业知识的特定内容,因此需要在回答中说明核医学医生是顾问,以指导患者和护理人员获得准确的医疗建议。就患者和护理人员寻求信息的信心和满意度而言,参考意义重大。
{"title":"Análisis de confiabilidad y lectibilidad de ChatGPT-4 y Google Gard como fuente de información del paciente para los tratamientos con radionúclidos más comúnmente aplicados en pacientes con cáncer","authors":"H. Şan ,&nbsp;Ö. Bayrakçi ,&nbsp;B. Çağdaş ,&nbsp;M. Serdengeçti ,&nbsp;E. Alagöz","doi":"10.1016/j.remn.2024.500021","DOIUrl":"10.1016/j.remn.2024.500021","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;p&gt;Searching for online health information is a popular approach employed by patients to enhance their knowledge for their diseases. Recently developed AI chatbots are probably the easiest way in this regard. The purpose of the study is to analyze the reliability and readability of AI chatbot responses in terms of the most commonly applied radionuclide treatments in cancer patients.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;Basic patient questions, thirty about RAI, PRRT and TARE treatments and twenty-nine about PSMA-TRT, were asked one by one to GPT-4 and Bard on January 2024. The reliability and readability of the responses were assessed by using DISCERN scale, Flesch Reading Ease(FRE) and Flesch-Kincaid Reading Grade Level(FKRGL).&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;The mean (SD) FKRGL scores for the responses of GPT-4 and Google Bard about RAI, PSMA-TRT, PRRT and TARE treatments were 14.57 (1.19), 14.65 (1.38), 14.25 (1.10), 14.38 (1.2) and 11.49 (1.59), 12.42 (1.71), 11.35 (1.80), 13.01 (1.97), respectively. In terms of readability the FRKGL scores of the responses of GPT-4 and Google Bard about RAI, PSMA-TRT, PRRT and TARE treatments were above the general public reading grade level. The mean (SD) DISCERN scores assesses by nuclear medicine phsician for the responses of GPT-4 and Bard about RAI, PSMA-TRT, PRRT and TARE treatments were 47.86 (5.09), 48.48 (4.22), 46.76 (4.09), 48.33 (5.15) and 51.50 (5.64), 53.44 (5.42), 53 (6.36), 49.43 (5.32), respectively. Based on mean DISCERN scores, the reliability of the responses of GPT-4 and Google Bard about RAI, PSMA-TRT, PRRT, and TARE treatments ranged from fair to good. The inter-rater reliability correlation coefficient of DISCERN scores assessed by GPT-4, Bard and nuclear medicine physician for the responses of GPT-4 about RAI, PSMA-TRT, PRRT and TARE treatments were 0.512 (95% CI 0.296: 0.704), 0.695 (95% CI 0.518: 0.829), 0.687 (95% CI 0.511: 0.823) and 0.649 (95% CI 0.462: 0.798), respectively (&lt;em&gt;P&lt;/em&gt;&lt;.01). The inter-rater reliability correlation coefficient of DISCERN scores assessed by GPT-4, Bard and nuclear medicine physician for the responses of Bard about RAI, PSMA-TRT, PRRT and TARE treatments were 0.753 (95% CI 0.602: 0.863), 0.812 (95% CI 0.686: 0.899), 0.804 (95% CI 0.677: 0.894) and 0.671 (95% CI 0.489: 0.812), respectively (&lt;em&gt;P&lt;/em&gt;&lt;.01). The inter-rater reliability for the responses of Bard and GPT-4 about RAİ, PSMA-TRT, PRRT and TARE treatments were moderate to good. Further, consulting to the nuclear medicine physician was rarely emphasized both in GPT-4 and Google Bard and references were included in some responses of Google Bard, but there were no references in GPT-4.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;Although the information provided by AI chatbots may be acceptable in medical terms, it can not be easy to read for the general public, which may prevent it from being understandable. Effective prompts using ‘prompt engineering’ may refine the responses","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 4","pages":"Article 500021"},"PeriodicalIF":1.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141839048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluación de la captación cardiaca incidental en la gammagrafía ósea en España: el estudio ECCINGO 西班牙骨闪烁成像中偶然摄取的心脏摄取量评估:ECCINGO 研究
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-07-01 DOI: 10.1016/j.remn.2024.500020
F.J. de Haro del Moral , S. Aguadé Bruix , M.J. Tabuenca Mateo , M.P. Tamayo Alonso , L. Mohamed Salem , L. Bernal , D. Primiano , P. Tarilonte

Aim

Myocardial uptake on bone scintigraphy has become useful for the detection of transthyretin cardiac amyloidosis (ATTR-CA). This study aimed to assess the prevalence of myocardial uptake in patients over 18 years of age with no clinical suspicion of cardiac amyloidosis (CA) who had undergone bone scintigraphy.

Methods and results

This was an observational, retrospective, multicenter study across 21 Spanish hospitals (September–November 2019). Of the 9864 scans analyzed (locally and centrally), incidental cardiac uptake was observed in 71 patients (0.72%), a prevalence that increased with age. A previous diagnosis of heart failure was found in 16.9% of patients with positive uptake, with >50% in NYHA II. ATTR-CA was diagnosed in 10 patients, with a mean delay of 10.4 months (95% CI: 5.1-15.7). All were >70 years old, primarily male, and had greater left ventricular hypertrophy than patients without a confirmed diagnosis (p< 0.0001). ATTR-CA patients had higher rates of orthostatic hypotension (30.0% vs. 3.8% in non-ATTR-CA; p = 0.025).

Conclusions

This is the first retrospective, national, multicenter study evaluating the prevalence of incidental cardiac uptake in bone scintigraphy performed for non-cardiac reasons, showing a prevalence of 0.72% in this population. Referral of these patients may facilitate early diagnosis of CA with a resulting benefit for patients.

目的 骨闪烁成像的心肌摄取已成为检测转甲状腺素心脏淀粉样变性(ATTR-CA)的有用方法。本研究旨在评估接受骨闪烁成像检查的 18 岁以上、临床上未怀疑患有心脏淀粉样变性(CA)的患者的心肌摄取率。方法和结果这是一项观察性、回顾性、多中心研究,涉及 21 家西班牙医院(2019 年 9 月至 11 月)。在分析的9864例扫描(局部和中央)中,71例患者(0.72%)观察到偶发性心脏摄取,其发生率随年龄增长而增加。16.9%的摄取阳性患者曾被诊断为心力衰竭,其中50%为NYHA II。10名患者确诊为ATTR-CA,平均延迟时间为10.4个月(95% CI:5.1-15.7)。与未确诊的患者相比,所有患者均为>70岁,主要为男性,左心室肥厚程度更高(p< 0.0001)。ATTR-CA患者的正张性低血压发生率较高(30.0% vs. 3.8% in non-ATTR-CA;p = 0.025)。结论这是第一项回顾性、全国性、多中心研究,评估了因非心脏原因进行骨闪烁扫描时意外摄取心脏信号的发生率,结果显示该人群的发生率为 0.72%。转诊这些患者可促进 CA 的早期诊断,从而使患者受益。
{"title":"Evaluación de la captación cardiaca incidental en la gammagrafía ósea en España: el estudio ECCINGO","authors":"F.J. de Haro del Moral ,&nbsp;S. Aguadé Bruix ,&nbsp;M.J. Tabuenca Mateo ,&nbsp;M.P. Tamayo Alonso ,&nbsp;L. Mohamed Salem ,&nbsp;L. Bernal ,&nbsp;D. Primiano ,&nbsp;P. Tarilonte","doi":"10.1016/j.remn.2024.500020","DOIUrl":"10.1016/j.remn.2024.500020","url":null,"abstract":"<div><h3>Aim</h3><p>Myocardial uptake on bone scintigraphy has become useful for the detection of transthyretin cardiac amyloidosis (ATTR-CA). This study aimed to assess the prevalence of myocardial uptake in patients over 18 years of age with no clinical suspicion of cardiac amyloidosis (CA) who had undergone bone scintigraphy.</p></div><div><h3>Methods and results</h3><p>This was an observational, retrospective, multicenter study across 21 Spanish hospitals (September–November 2019). Of the 9864 scans analyzed (locally and centrally), incidental cardiac uptake was observed in 71 patients (0.72%), a prevalence that increased with age. A previous diagnosis of heart failure was found in 16.9% of patients with positive uptake, with<!--> <!-->&gt;50% in NYHA II. ATTR-CA was diagnosed in 10 patients, with a mean delay of 10.4 months (95% CI: 5.1-15.7). All were<!--> <!-->&gt;70 years old, primarily male, and had greater left ventricular hypertrophy than patients without a confirmed diagnosis (<em>p</em>&lt;<!--> <!-->0.0001). ATTR-CA patients had higher rates of orthostatic hypotension (30.0% vs. 3.8% in non-ATTR-CA; p<!--> <!-->=<!--> <!-->0.025).</p></div><div><h3>Conclusions</h3><p>This is the first retrospective, national, multicenter study evaluating the prevalence of incidental cardiac uptake in bone scintigraphy performed for non-cardiac reasons, showing a prevalence of 0.72% in this population. Referral of these patients may facilitate early diagnosis of CA with a resulting benefit for patients.</p></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 4","pages":"Article 500020"},"PeriodicalIF":1.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2253654X24000283/pdfft?md5=9b700d264c6d0de207d3419e4e63f693&pid=1-s2.0-S2253654X24000283-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141951740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Actualización sobre la protección radiológica de la glándula tiroides 甲状腺辐射防护的最新情况
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-07-01 DOI: 10.1016/j.remn.2024.500026
M. Negre , S. Agramunt , N. Ferran , P. Paredes

In recent years, concern about the effects of ionizing radiation on exposed individuals has led to the need to regulate and quantify the use of diagnostic and therapeutic techniques. Geopolitical events in recent times have also increased the population's perception of insecurity regarding ionizing radiation, and we increasingly face patients reluctant to undergo certain types of scans in our nuclear medicine services and, albeit less frequently, in radiology services. This article aims to summarise the extent to which ionizing radiation is present in our daily lives and how diagnostic and therapeutic procedures can affect our health, particularly from the perspective of their effects on the thyroid gland, one of the body's most radiation-sensitive organs.

近年来,由于人们担心电离辐射会对受到辐射的个人产生影响,因此需要对诊断和治疗技术的使用进行规范和量化。近来发生的地缘政治事件也增加了人们对电离辐射的不安全感,我们的核医学服务中越来越多的病人不愿接受某些类型的扫描,放射学服务中也有病人不愿接受扫描,尽管这种情况并不常见。本文旨在总结电离辐射在我们日常生活中的存在程度,以及诊断和治疗程序如何影响我们的健康,特别是从它们对人体对辐射最敏感的器官之一--甲状腺的影响的角度进行分析。
{"title":"Actualización sobre la protección radiológica de la glándula tiroides","authors":"M. Negre ,&nbsp;S. Agramunt ,&nbsp;N. Ferran ,&nbsp;P. Paredes","doi":"10.1016/j.remn.2024.500026","DOIUrl":"10.1016/j.remn.2024.500026","url":null,"abstract":"<div><p>In recent years, concern about the effects of ionizing radiation on exposed individuals has led to the need to regulate and quantify the use of diagnostic and therapeutic techniques. Geopolitical events in recent times have also increased the population's perception of insecurity regarding ionizing radiation, and we increasingly face patients reluctant to undergo certain types of scans in our nuclear medicine services and, albeit less frequently, in radiology services. This article aims to summarise the extent to which ionizing radiation is present in our daily lives and how diagnostic and therapeutic procedures can affect our health, particularly from the perspective of their effects on the thyroid gland, one of the body's most radiation-sensitive organs.</p></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 4","pages":"Article 500026"},"PeriodicalIF":1.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141951754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identificación de ganglio centinela axilar no detectado en cáncer de mama tratado con quimioterapia neoadyuvante 鉴定新辅助化疗乳腺癌患者未检测到的腋窝前哨结节
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-07-01 DOI: 10.1016/j.remn.2024.500024
A. García-Ruiz, I. Martínez-Rodríguez, N. Martínez-Amador, N.V. Carvalho-Duarte, J. Jiménez-Bonilla, R. Quirce
{"title":"Identificación de ganglio centinela axilar no detectado en cáncer de mama tratado con quimioterapia neoadyuvante","authors":"A. García-Ruiz,&nbsp;I. Martínez-Rodríguez,&nbsp;N. Martínez-Amador,&nbsp;N.V. Carvalho-Duarte,&nbsp;J. Jiménez-Bonilla,&nbsp;R. Quirce","doi":"10.1016/j.remn.2024.500024","DOIUrl":"10.1016/j.remn.2024.500024","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 4","pages":"Article 500024"},"PeriodicalIF":1.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141951757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Descifrando el futuro: desafíos y oportunidades de la medicina nuclear 解读未来:核医学的挑战与机遇
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-07-01 DOI: 10.1016/j.remn.2024.500036
J.R. Garcia, R. Jover, M. Mila, A. Muxi, V. Vallejos, A. Garcia, E. Caballero
{"title":"Descifrando el futuro: desafíos y oportunidades de la medicina nuclear","authors":"J.R. Garcia,&nbsp;R. Jover,&nbsp;M. Mila,&nbsp;A. Muxi,&nbsp;V. Vallejos,&nbsp;A. Garcia,&nbsp;E. Caballero","doi":"10.1016/j.remn.2024.500036","DOIUrl":"10.1016/j.remn.2024.500036","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 4","pages":"Article 500036"},"PeriodicalIF":1.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141843606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista Espanola De Medicina Nuclear E Imagen Molecular
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1